TrialCardiovascular diabetology2022

Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report.

Lucia Leccisotti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.